Logo

Amicus Therapeutics' Galafold (migalastat) Receives FDA Approval for Fabry Disease in Adult Patients

Share this

Amicus Therapeutics' Galafold (migalastat) Receives FDA Approval for Fabry Disease in Adult Patients

Shots:

  • The approval is based on P-III FACET or Study 011 results assessing Galafold (150mg) in patient with Fabry Disease- evaluating its safety and efficacy
  • The FACET or Study 011 resulted in reduction of substrate (KIC GL-3) accumulation in the kidney capillaries
  • Galafold (migalastat) 123mg is a novel PO dosage form of alpha Galactosidase A used for Fabry Disease in adults and is approved in the US- EU- Australia- Canada- Israel- Japan- South Korea & Switzerland

Ref: Amicus Therapeutics | Image: Reuters

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions